SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-198589
Filing Date
2023-07-31
Accepted
2023-07-31 08:12:52
Documents
13
Period of Report
2023-07-31
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d518650d8k.htm   iXBRL 8-K 34214
2 EX-99.1 d518650dex991.htm EX-99.1 14879
  Complete submission text file 0001193125-23-198589.txt   180240

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA spro-20230731.xsd EX-101.SCH 2877
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE spro-20230731_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE spro-20230731_pre.xml EX-101.PRE 11279
7 EXTRACTED XBRL INSTANCE DOCUMENT d518650d8k_htm.xml XML 3350
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38266 | Film No.: 231125136
SIC: 2834 Pharmaceutical Preparations